PT  - JOURNAL ARTICLE
AU  - Murugadoss, Karthik
AU  - Niesen, Michiel J.M.
AU  - Raghunathan, Bharathwaj
AU  - Lenehan, Patrick J.
AU  - Ghosh, Pritha
AU  - Feener, Tyler
AU  - Anand, Praveen
AU  - Simsek, Safak
AU  - Suratekar, Rohit
AU  - Hughes, Travis K.
AU  - Soundararajan, Venky
TI  - Continuous genomic diversification of long polynucleotide fragments drives the emergence of new SARS-CoV-2 variants of concern
AID  - 10.1101/2021.12.23.21268315
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.23.21268315
4099  - http://medrxiv.org/content/early/2022/01/06/2021.12.23.21268315.short
4100  - http://medrxiv.org/content/early/2022/01/06/2021.12.23.21268315.full
AB  - Highly transmissible or immuno-evasive SARS-CoV-2 variants have intermittently emerged and outcompeted previously circulating strains, resulting in repeated COVID-19 surges, reinfections, and breakthrough infections in vaccinated individuals. With over 5 million SARS-CoV-2 genomes sequenced globally over the last 2 years, there is unprecedented data to decipher how competitive viral evolution results in the emergence of fitter SARS-CoV-2 variants. Much attention has been directed to studying how specific mutations in the Spike protein impact its binding to the ACE2 receptor or viral neutralization by antibodies, but there is limited knowledge of a genomic signature that is shared primarily by the sequential dominant variants. Here we introduce a methodology to quantify the genome-wide distinctiveness of polynucleotide fragments of various lengths (3-to 240-mers) that constitute SARS-CoV-2 sequences (freely available at https://academia.nferx.com/GENI). Compared to standard phylogenetic distance metrics and overall mutational load, the quantification of distinctive 9-mer polynucleotides provides a higher resolution of separation between VOCs (Reference = 89, IQR: 65-108; Alpha = 166, IQR: 150-182; Beta 130, IQR: 113-147; Gamma = 165, IQR: 152-180; Delta = 234, IQR: 216-253; and Omicron = 294, IQR: 287-315). Omicron’s exceptionally high genomic distinctiveness may confer a competitive advantage over both prior VOCs (including Delta) and the recently emerged and highly mutated B.1.640.2 (IHU) lineage. Expanding on this analysis, evaluation of genomic distinctiveness weighted by intra-lineage 9-mer conservation for 1,363 lineages annotated in GISAID highlights that genomic distinctiveness has increased over time (R2=0.37) and that VOCs score significantly higher than contemporary non-VOC lineages, with Omicron among the most distinctive lineages observed till date. This study demonstrates the value of characterizing new SARS-CoV-2 variants by their genome-wide polynucleotide distinctiveness and emphasizes the need to go beyond a narrow set of mutations at known functionally or antigenically salient sites on the Spike protein. The consistently higher distinctiveness of each emerging VOC compared to prior VOCs suggests that real-time monitoring of genomic distinctiveness would aid in more rapid assessment of viral fitness.Competing Interest StatementKM, MJMN, BR, PJL, PG, PA, TF, SS, RS, TJH and VS are employees of nference and have financial interests in the company. nference collaborates with health systems, bio-pharmaceutical companies, and academic medical centers on data science initiatives unrelated to this study. These collaborations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. KM, MJMN, BR, and VS are named inventors on a provisional patent application related to this study.Funding StatementThis study was funded by nference (https://nference.com) and did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://academia.nferx.com/GENI https://academia.nferx.com/GENI